These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
359 related items for PubMed ID: 23737602
1. A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic Escherichia coli ST131. Totsika M, Kostakioti M, Hannan TJ, Upton M, Beatson SA, Janetka JW, Hultgren SJ, Schembri MA. J Infect Dis; 2013 Sep; 208(6):921-8. PubMed ID: 23737602 [Abstract] [Full Text] [Related]
2. Insights into a multidrug resistant Escherichia coli pathogen of the globally disseminated ST131 lineage: genome analysis and virulence mechanisms. Totsika M, Beatson SA, Sarkar S, Phan MD, Petty NK, Bachmann N, Szubert M, Sidjabat HE, Paterson DL, Upton M, Schembri MA. PLoS One; 2011 Sep; 6(10):e26578. PubMed ID: 22053197 [Abstract] [Full Text] [Related]
4. Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist. Spaulding CN, Klein RD, Ruer S, Kau AL, Schreiber HL, Cusumano ZT, Dodson KW, Pinkner JS, Fremont DH, Janetka JW, Remaut H, Gordon JI, Hultgren SJ. Nature; 2017 Jun 22; 546(7659):528-532. PubMed ID: 28614296 [Abstract] [Full Text] [Related]
5. Human Urine Decreases Function and Expression of Type 1 Pili in Uropathogenic Escherichia coli. Greene SE, Hibbing ME, Janetka J, Chen SL, Hultgren SJ. mBio; 2015 Jun 30; 6(4):e00820. PubMed ID: 26126855 [Abstract] [Full Text] [Related]
6. Biofilm formation by multidrug resistant Escherichia coli ST131 is dependent on type 1 fimbriae and assay conditions. Sarkar S, Vagenas D, Schembri MA, Totsika M. Pathog Dis; 2016 Apr 30; 74(3):. PubMed ID: 26940589 [Abstract] [Full Text] [Related]
7. Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease. Mydock-McGrane LK, Hannan TJ, Janetka JW. Expert Opin Drug Discov; 2017 Jul 30; 12(7):711-731. PubMed ID: 28506090 [Abstract] [Full Text] [Related]
8. Systemic immunization with conserved pilus-associated adhesins protects against mucosal infections. Palaszynski S, Pinkner J, Leath S, Barren P, Auguste CG, Burlein J, Hultgren S, Langermann S. Dev Biol Stand; 1998 Jul 30; 92():117-22. PubMed ID: 9554264 [Abstract] [Full Text] [Related]
9. Localization of a domain in the FimH adhesin of Escherichia coli type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection. Thankavel K, Madison B, Ikeda T, Malaviya R, Shah AH, Arumugam PM, Abraham SN. J Clin Invest; 1997 Sep 01; 100(5):1123-36. PubMed ID: 9276729 [Abstract] [Full Text] [Related]
10. Single clinical isolates from acute uncomplicated urinary tract infections are representative of dominant in situ populations. Willner D, Low S, Steen JA, George N, Nimmo GR, Schembri MA, Hugenholtz P. mBio; 2014 Feb 25; 5(2):e01064-13. PubMed ID: 24570371 [Abstract] [Full Text] [Related]
11. Comprehensive analysis of type 1 fimbriae regulation in fimB-null strains from the multidrug resistant Escherichia coli ST131 clone. Sarkar S, Roberts LW, Phan MD, Tan L, Lo AW, Peters KM, Paterson DL, Upton M, Ulett GC, Beatson SA, Totsika M, Schembri MA. Mol Microbiol; 2016 Sep 25; 101(6):1069-87. PubMed ID: 27309594 [Abstract] [Full Text] [Related]
12. A Murine Model for Escherichia coli Urinary Tract Infection. Hannan TJ, Hunstad DA. Methods Mol Biol; 2016 Sep 25; 1333():159-75. PubMed ID: 26468108 [Abstract] [Full Text] [Related]
13. A cynomolgus monkey E. coli urinary tract infection model confirms efficacy of new FimH vaccine candidates. Chorro L, Ciolino T, Torres CL, Illenberger A, Aglione J, Corts P, Lypowy J, Ponce C, La Porte A, Burt D, Volberg GL, Ramaiah L, McGovern K, Hu J, Anderson AS, Silmon de Monerri NC, Kanevsky I, Donald RGK. Infect Immun; 2024 Oct 15; 92(10):e0016924. PubMed ID: 39297649 [Abstract] [Full Text] [Related]
14. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Langermann S, Palaszynski S, Barnhart M, Auguste G, Pinkner JS, Burlein J, Barren P, Koenig S, Leath S, Jones CH, Hultgren SJ. Science; 1997 Apr 25; 276(5312):607-11. PubMed ID: 9110982 [Abstract] [Full Text] [Related]
15. Escherichia coli ST131-H22 as a Foodborne Uropathogen. Liu CM, Stegger M, Aziz M, Johnson TJ, Waits K, Nordstrom L, Gauld L, Weaver B, Rolland D, Statham S, Horwinski J, Sariya S, Davis GS, Sokurenko E, Keim P, Johnson JR, Price LB. mBio; 2018 Aug 28; 9(4):. PubMed ID: 30154256 [Abstract] [Full Text] [Related]
16. Population dynamics and niche distribution of uropathogenic Escherichia coli during acute and chronic urinary tract infection. Schwartz DJ, Chen SL, Hultgren SJ, Seed PC. Infect Immun; 2011 Oct 28; 79(10):4250-9. PubMed ID: 21807904 [Abstract] [Full Text] [Related]
17. Differential Afa/Dr Fimbriae Expression in the Multidrug-Resistant Escherichia coli ST131 Clone. Alvarez-Fraga L, Phan MD, Goh KGK, Nhu NTK, Hancock SJ, Allsopp LP, Peters KM, Forde BM, Roberts LW, Sullivan MJ, Totsika M, Beatson SA, Ulett GC, Schembri MA. mBio; 2022 Feb 22; 13(1):e0351921. PubMed ID: 35038925 [Abstract] [Full Text] [Related]